Alogliptin, but not voglibose, ameliorates dyslipidemia and LDL particle size in patients with impaired glucose tolerance or Type 2 diabetes

Author: Aramaki Masanobu  

Publisher: Future Medicine

ISSN: 1758-4299

Source: Clinical Lipidology, Vol.8, Iss.5, 2013-10, pp. : 533-540

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content